<p>Organon &amp; Co. (NYSE:OGN - 获取免费报告) 的股价在周五达到了新的 52 周低点。该股最低交易价为$13.25，最后交易价为$13.18，成交量为 785212 股。该股之前的收盘价为$14.45。</p>
<p>获取 <strong>Organon &amp; Co.</strong> 的提醒：</p>
<h2>华尔街分析师观点</h2>
<ul>
<li>道琼斯最热门的股票默克准备发布第四季度财报</li>
</ul>
<p>几位研究分析师最近对该公司发布了报告。摩根士丹利在 2 月 14 日的研究报告中将 Organon &amp; Co.的目标价从$17.00 下调至$16.00，并给予该公司 “持平” 评级。TD Cowen 在 1 月 15 日的研究报告中将 Organon &amp; Co.的股票评级上调至 “持有”。最后，巴克莱在 2 月 14 日的研究报告中将 Organon &amp; Co.的目标价从$26.00 下调至$24.00，并给予该公司 “增持” 评级。一位分析师对该股给予了卖出评级，三位分析师给予了持有评级，两位分析师给予了买入评级，一位分析师给予了强烈买入评级。根据 MarketBeat.com 的数据，该股目前的平均评级为 “持有”，平均目标价为$20.80。</p>
<p><strong>阅读我们最新的 Organon &amp; Co.股票报告</strong></p>
<h2>Organon &amp; Co. 股价下跌 9.6%</h2>
<ul>
<li>Lululemon Athletica 因进入标准普尔 500 指数而创下新高</li>
</ul>
<p>该公司的 50 日简单移动平均线为$15.22，200 日简单移动平均线为$16.10。该公司的市值为 33.7 亿美元，市盈率为 3.92，市盈增长比率为 0.90，贝塔值为 0.76。该公司的速动比率为 1.21，流动比率为 1.70，债务股本比率为 17.73。</p>
<p>Organon &amp; Co. (NYSE:OGN - 获取免费报告) 最近在 2 月 13 日发布了季度财报。该公司报告每股收益（EPS）为$0.83，低于市场共识预期的$0.92，差额为 ($0.09)。Organon &amp; Co.的股本回报率为 431.62%，净利润率为 13.49%。该公司本季度的收入为 15.9 亿美元，而市场共识预期为 15.7 亿美元。股票分析师预计 Organon &amp; Co.在当前年度的每股收益将达到 3.68。</p>
<h2>Organon &amp; Co. 分红公告</h2>
<p>该公司最近宣布了季度分红，已于 3 月 13 日支付。2 月 24 日的登记投资者获得了$0.28 的分红。该分红的除息日期为 2 月 24 日。这代表着年化分红为$1.12，分红收益率为 8.57%。Organon &amp; Co.的派息比率目前为 33.63%。</p>
<h2>Organon &amp; Co. 的机构交易</h2>
<p>机构投资者最近对该股票的持仓进行了调整。Quantbot Technologies LP 在第三季度购买了 Organon &amp; Co.的新股份，价值约为$113,000。苏黎世州立银行在第三季度将其在 Organon &amp; Co.的持仓提高了 8.4%。苏黎世州立银行现在拥有该公司 55,506 股股票，价值$1,062,000，此前在该期间又购买了 4,298 股。瑞银资产管理美国有限公司的一个独立业务单位在第三季度将其在 Organon &amp; Co.的持仓提高了 0.5%。瑞银资产管理美国有限公司的一个独立业务单位现在拥有 836,389 股该公司的股票，价值$16,000,000，此前在上个季度又购买了 4,029 股。Verition Fund Management LLC 在第三季度购买了 Organon &amp; Co.的新股份，价值$195,000。最后，Paloma Partners Management Co 在第三季度购买了 Organon &amp; Co.的股份，价值约为$362,000。对冲基金和其他机构投资者持有该公司 77.43% 的股票。</p>
<h2>Organon &amp; Co. 公司简介</h2>
<p>(获取免费报告)</p>
<p>Organon &amp; Co.是一家基于科学的全球制药公司，致力于通过一系列处方疗法在女性健康、生物类似药和成熟品牌领域开发和提供创新健康解决方案。该公司成立于 2020 年 3 月 11 日，总部位于新泽西州泽西市。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比 Organon &amp; Co.更好</li>
<li>内部人士买入解释：投资者需要知道的事项</li>
<li>Archer Aviation 在非洲的交易可能提升 ACHR 股票</li>
<li>投资便士股票需要知道的事项</li>
<li>空头卖家对这三只半导体股票是否错误？</li>
<li>投资建筑股票</li>
<li>波音在 3 月份获得 500 亿美元订单——BA 股票现在值得买吗？</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Organon &amp; Co.吗？</h2>
<p>在考虑投资 Organon &amp; Co.之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Organon &amp; Co.并不在名单上。</p>
<p>虽然 Organon &amp; Co.目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>Organon & Co.（纽约证券交易所代码：OGN）达到了新的 52 周低点 13.18 美元，较之前的收盘价 14.45 美元下跌。分析师的评级意见不一，摩根士丹利将其目标价下调至 16.00 美元，巴克莱则将目标价降低至 24.00 美元。该股票的平均评级为 “持有”，目标价为 20.80 美元。公司报告第四季度每股收益为 0.83 美元，未达到预期，并宣布季度股息为 0.28 美元。机构投资者持有该股票的 77.43%，显示出尽管近期价格下跌，仍然有强烈的投资兴趣</p>

<p>Organon &amp; Co. (NYSE:OGN - Get Free Report)'s stock price reached a new 52-week low on Friday . The stock traded as low as $13.25 and last traded at $13.18, with a volume of 785212 shares. The stock had previously closed at $14.45.</p>
<div class="lb-trans"><p>Organon &amp; Co. (NYSE:OGN - 获取免费报告) 的股价在周五达到了新的 52 周低点。该股最低交易价为$13.25，最后交易价为$13.18，成交量为 785212 股。该股之前的收盘价为$14.45。</p>
</div><p>Get <strong>Organon &amp; Co.</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Organon &amp; Co.</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><ul>
<li>Merck, the Dow's hottest stock, gets set to report Q4 financials</li>
</ul>
<div class="lb-trans"><ul>
<li>道琼斯最热门的股票默克准备发布第四季度财报</li>
</ul>
</div><p>Several research analysts recently issued reports on the company. Morgan Stanley lowered their target price on Organon &amp; Co. from $17.00 to $16.00 and set an &#34;equal weight&#34; rating for the company in a research report on Friday, February 14th. TD Cowen raised shares of Organon &amp; Co. to a &#34;hold&#34; rating in a research report on Wednesday, January 15th. Finally, Barclays decreased their target price on Organon &amp; Co. from $26.00 to $24.00 and set an &#34;overweight&#34; rating for the company in a research report on Friday, February 14th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of &#34;Hold&#34; and an average price target of $20.80.</p>
<div class="lb-trans"><p>几位研究分析师最近对该公司发布了报告。摩根士丹利在 2 月 14 日的研究报告中将 Organon &amp; Co.的目标价从$17.00 下调至$16.00，并给予该公司 “持平” 评级。TD Cowen 在 1 月 15 日的研究报告中将 Organon &amp; Co.的股票评级上调至 “持有”。最后，巴克莱在 2 月 14 日的研究报告中将 Organon &amp; Co.的目标价从$26.00 下调至$24.00，并给予该公司 “增持” 评级。一位分析师对该股给予了卖出评级，三位分析师给予了持有评级，两位分析师给予了买入评级，一位分析师给予了强烈买入评级。根据 MarketBeat.com 的数据，该股目前的平均评级为 “持有”，平均目标价为$20.80。</p>
</div><p><strong>Read Our Latest Stock Report on Organon &amp; Co.</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的 Organon &amp; Co.股票报告</strong></p>
</div><h2>Organon &amp; Co. Trading Down 9.6 %</h2>
<div class="lb-trans"><h2>Organon &amp; Co. 股价下跌 9.6%</h2>
</div><ul>
<li>Lululemon Athletica Races to New High with S&amp;P 500 Entry</li>
</ul>
<div class="lb-trans"><ul>
<li>Lululemon Athletica 因进入标准普尔 500 指数而创下新高</li>
</ul>
</div><p>The firm's 50-day simple moving average is $15.22 and its 200-day simple moving average is $16.10. The firm has a market capitalization of $3.37 billion, a PE ratio of 3.92, a price-to-earnings-growth ratio of 0.90 and a beta of 0.76. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73.</p>
<div class="lb-trans"><p>该公司的 50 日简单移动平均线为$15.22，200 日简单移动平均线为$16.10。该公司的市值为 33.7 亿美元，市盈率为 3.92，市盈增长比率为 0.90，贝塔值为 0.76。该公司的速动比率为 1.21，流动比率为 1.70，债务股本比率为 17.73。</p>
</div><p>Organon &amp; Co. (NYSE:OGN - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon &amp; Co. had a return on equity of 431.62% and a net margin of 13.49%. The company had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.57 billion. Equities analysts expect that Organon &amp; Co. will post 3.68 earnings per share for the current year.</p>
<div class="lb-trans"><p>Organon &amp; Co. (NYSE:OGN - 获取免费报告) 最近在 2 月 13 日发布了季度财报。该公司报告每股收益（EPS）为$0.83，低于市场共识预期的$0.92，差额为 ($0.09)。Organon &amp; Co.的股本回报率为 431.62%，净利润率为 13.49%。该公司本季度的收入为 15.9 亿美元，而市场共识预期为 15.7 亿美元。股票分析师预计 Organon &amp; Co.在当前年度的每股收益将达到 3.68。</p>
</div><h2>Organon &amp; Co. Dividend Announcement</h2>
<div class="lb-trans"><h2>Organon &amp; Co. 分红公告</h2>
</div><p>The business also recently declared a quarterly dividend, which was paid on Thursday, March 13th. Investors of record on Monday, February 24th were paid a $0.28 dividend. The ex-dividend date of this dividend was Monday, February 24th. This represents a $1.12 annualized dividend and a dividend yield of 8.57%. Organon &amp; Co.'s payout ratio is currently 33.63%.</p>
<div class="lb-trans"><p>该公司最近宣布了季度分红，已于 3 月 13 日支付。2 月 24 日的登记投资者获得了$0.28 的分红。该分红的除息日期为 2 月 24 日。这代表着年化分红为$1.12，分红收益率为 8.57%。Organon &amp; Co.的派息比率目前为 33.63%。</p>
</div><h2>Institutional Trading of Organon &amp; Co.</h2>
<div class="lb-trans"><h2>Organon &amp; Co. 的机构交易</h2>
</div><p>Institutional investors have recently made changes to their positions in the stock. Quantbot Technologies LP purchased a new stake in Organon &amp; Co. in the third quarter worth about $113,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Organon &amp; Co. by 8.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 55,506 shares of the company's stock valued at $1,062,000 after purchasing an additional 4,298 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Organon &amp; Co. by 0.5% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 836,389 shares of the company's stock valued at $16,000,000 after buying an additional 4,029 shares in the last quarter. Verition Fund Management LLC bought a new position in Organon &amp; Co. in the 3rd quarter worth $195,000. Finally, Paloma Partners Management Co bought a new position in shares of Organon &amp; Co. in the third quarter worth about $362,000. Hedge funds and other institutional investors own 77.43% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近对该股票的持仓进行了调整。Quantbot Technologies LP 在第三季度购买了 Organon &amp; Co.的新股份，价值约为$113,000。苏黎世州立银行在第三季度将其在 Organon &amp; Co.的持仓提高了 8.4%。苏黎世州立银行现在拥有该公司 55,506 股股票，价值$1,062,000，此前在该期间又购买了 4,298 股。瑞银资产管理美国有限公司的一个独立业务单位在第三季度将其在 Organon &amp; Co.的持仓提高了 0.5%。瑞银资产管理美国有限公司的一个独立业务单位现在拥有 836,389 股该公司的股票，价值$16,000,000，此前在上个季度又购买了 4,029 股。Verition Fund Management LLC 在第三季度购买了 Organon &amp; Co.的新股份，价值$195,000。最后，Paloma Partners Management Co 在第三季度购买了 Organon &amp; Co.的股份，价值约为$362,000。对冲基金和其他机构投资者持有该公司 77.43% 的股票。</p>
</div><h2>Organon &amp; Co. Company Profile</h2>
<div class="lb-trans"><h2>Organon &amp; Co. 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Organon &amp; Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.</p>
<div class="lb-trans"><p>Organon &amp; Co.是一家基于科学的全球制药公司，致力于通过一系列处方疗法在女性健康、生物类似药和成熟品牌领域开发和提供创新健康解决方案。该公司成立于 2020 年 3 月 11 日，总部位于新泽西州泽西市。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Organon &amp; Co.</li>
<li>Insider Buying Explained: What Investors Need to Know</li>
<li>Archer Aviation’s Africa Deal Could Boost ACHR Stock</li>
<li>What to Know About Investing in Penny Stocks</li>
<li>Are Short Sellers Wrong About These 3 Semiconductor Stocks?</li>
<li>Investing in Construction Stocks</li>
<li>Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Organon &amp; Co.更好</li>
<li>内部人士买入解释：投资者需要知道的事项</li>
<li>Archer Aviation 在非洲的交易可能提升 ACHR 股票</li>
<li>投资便士股票需要知道的事项</li>
<li>空头卖家对这三只半导体股票是否错误？</li>
<li>投资建筑股票</li>
<li>波音在 3 月份获得 500 亿美元订单——BA 股票现在值得买吗？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Organon &amp; Co. Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Organon &amp; Co.吗？</h2>
</div><p>Before you consider Organon &amp; Co., you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Organon &amp; Co.之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon &amp; Co. wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Organon &amp; Co.并不在名单上。</p>
</div><p>While Organon &amp; Co. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Organon &amp; Co.目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Organon & Co. (NYSE:OGN) 创下新的 12 个月低点 - 你应该卖出吗？